Pneumocystis A12 Antigen Expression via Segmentation and Codon Optimization
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for developing a vaccine against Pneumocystis pneumonia are hindered by the inability to culture Pneumocystis outside a host and host species-specificity, leading to ineffective treatments and challenges in producing the A12 protein due to problematic codons at the N-terminus.
Innovation Solution
The development of an isolated Pneumocystis A12 protein and nucleic acid molecules encoding the protein, expressed as two half-length segments with the C-terminal half expressed well and the N-terminal half as a thioredoxin fusion, and a larger fragment omitting problematic codons to facilitate immunization, along with the use of immunogenic conjugates and antibodies for protection.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If the full-length A12 protein is expressed using the native gene sequence, then the complete antigen is produced, but expression fails due to problematic codons at the N-terminus
Solution Approach 1:
The patent removes the problematic N-terminal region (first 15 codons) containing problematic codons from the A12 gene sequence. This extraction eliminates the expression barrier while preserving the immunogenic C-terminal portion of the antigen, enabling successful protein production in E. coli that would otherwise fail with the native sequence
Solution Approach 2:
The patent modifies the gene sequence parameters by altering the N-terminal codon region while maintaining the reading frame. This sequence optimization changes the translational properties of the gene, removing codons that cause expression failures in E. coli while preserving the antigen's functional and immunogenic properties
2Ease of manufacture
If the A12 protein is divided into two half-length segments for expression, then the N-terminal half can be expressed as a thioredoxin fusion, but the C-terminal half alone provides only slight protection
Solution Approach 1:
The patent divides the A12 antigen into two separate expression constructs: an N-terminal half fused to thioredoxin for enhanced expression and stability, and a C-terminal half expressed separately. This segmentation allows each fragment to be optimized for bacterial expression while maintaining immunogenicity, with the N-terminal fusion providing substantial protection
3Reliability
If host species-specific antigens are used for immunization, then the antigen is highly immunogenic in the source host, but it does not cross-react with antigens from other species
Solution Approach 1:
The patent identifies and utilizes conserved regions within the A12 antigen that are shared across different Pneumocystis species. By focusing on these universal epitopes, the vaccine achieves broad cross-species protection while maintaining high immunogenicity, making the vaccine applicable to multiple host species including humans, mice, and other mammals
Data Source
AI summary
Immunologically active agents are described, including isolated Pneumocystis A 12 protein or polypeptides; immunogenic conjugates containing Pneumocystis A 12 protein or polypeptide of the present invention; antibodies recognizing the Pneumocystis A 12 protein or polypeptide or the immunogenic conjugates of the present invention; and nucleic acid molecules that encode the Pneumocystis A 12 protein or polypeptide of the present invention, as well as DNA constructs, expression vectors, and host cells that contain the nucleic acid molecules. Disclosed uses of the antibodies, immunogenic conjugates, and DNA constructs include inducing passive or active immunity to treat or prevent pathogen infections, particularly by a Pneumocystis organism, in a subject.